These sources describe the need. They aren't results for Protocols itself, which still needs product-specific testing.
60.2% of US adults aged 20+ used a dietary supplement; 38.7% used two or more in the past 30 days.
CDC / NCHS Data Brief 561, May 2026. NHANES August 2021–August 2023. These figures describe use, not harm or Protocols outcomes.
Read the sourceThom et al. reported a 1.08-day between-group improvement in self-reported medication-adherent days per week with primary-care health coaching.
2015, 12-month trial. Evidence for that coaching intervention, not evidence that Kokorology improves adherence.
Read the sourceThe STEP-1 exploratory DXA substudy reported a 9.7% reduction in lean body mass in the semaglutide group at 68 weeks.
2021; 140 scanned participants. Lean body mass is not the same as skeletal muscle or strength. This does not establish that non-adherence caused the change.
Read the sourceA 2025 multi-society advisory describes nutrition, physical activity and individualised support during GLP-1 treatment.
Clinical guidance, not a trial of Protocols. Medication and treatment decisions remain with the prescriber.
Read the sourceLabel upload, combined vitamin and mineral totals, timing flags and monthly review in Protocols.
Digital access and existing Journal subscriptions, with Daily Practice Hacks included.
Semaglutide, tirzepatide, clinical evidence and boundaries for treatment support.
Browse targeted paid protocols for recovery, sleep, stress and everyday capacity.
Understand nervous-system regulation and its place in everyday practice.
Browse the public research library and its study summaries.
Short nervous-system practices for daily routines.
Explore custom-branded support; broader shared coach–doctor workspaces are planned.